BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33841677)

  • 1. Role of kynurenine in promoting the generation of exhausted CD8
    Wu D; Zhu Y
    Am J Transl Res; 2021; 13(3):1535-1547. PubMed ID: 33841677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Fong W; Li Q; Ji F; Liang W; Lau HCH; Kang X; Liu W; To KK; Zuo Z; Li X; Zhang X; Sung JJ; Yu J
    Gut; 2023 Nov; 72(12):2272-2285. PubMed ID: 37770127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice.
    Zhang R; Wang Y; Liu D; Luo Q; Du P; Zhang H; Wu W
    Front Pharmacol; 2022; 13():870848. PubMed ID: 35571116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
    Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
    Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion.
    Shang K; Wang Z; Hu Y; Huang Y; Yuan K; Yu Y
    Oncol Lett; 2020 Jun; 19(6):3827-3838. PubMed ID: 32382333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Repopulating Cells Induce PD-1 Expression in CD8
    Liu Y; Liang X; Dong W; Fang Y; Lv J; Zhang T; Fiskesund R; Xie J; Liu J; Yin X; Jin X; Chen D; Tang K; Ma J; Zhang H; Yu J; Yan J; Liang H; Mo S; Cheng F; Zhou Y; Zhang H; Wang J; Li J; Chen Y; Cui B; Hu ZW; Cao X; Xiao-Feng Qin F; Huang B
    Cancer Cell; 2018 Mar; 33(3):480-494.e7. PubMed ID: 29533786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
    Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
    Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID5A stabilizes Indoleamine 2,3-dioxygenase expression and enhances CAR T cell exhaustion in colorectal cancer.
    Wu D; Wang G; Wen S; Liu X; He Q
    Transl Oncol; 2024 Apr; 42():101900. PubMed ID: 38316094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism.
    Yang Q; Hao J; Chi M; Wang Y; Xin B; Huang J; Lu J; Li J; Sun X; Li C; Huo Y; Zhang J; Han Y; Guo C
    Oncoimmunology; 2022; 11(1):2055703. PubMed ID: 35355679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Liposome nanoparticles for targeted delivery of parthenolide induce colorectal cancer necroptosis to ameliorate tumor-infiltrating T cell exhaustion in mice].
    Yao W; Wang X; Yang Y; You J; Jin J; Zeng P; Han Q; Yao X; Sun X; Zhou J
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1674-1681. PubMed ID: 37933642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
    Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
    Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer.
    Shen F; Feng L; Zhu Y; Tao D; Xu J; Peng R; Liu Z
    Biomaterials; 2020 Oct; 255():120190. PubMed ID: 32563943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.